ICCC
What one share of ImmuCell holds
In Vitro and In Vivo Diagnostic Substances
ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves.
ImmuCell’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.38 |
|---|---|
| Profit | $0.09 |
| Capex (buildings and equipment) | $0.18 |
| Free cash flow | $0.46 |
| Cash and investments | $0.98 |
| Debt | $0.91 |
| Book value | $3.45 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.20 | $0.12 | $0.83 | −$0.88 | — | $4.07 |
| 2017 | $2.11 | −$0.03 | $3.59 | −$3.35 | — | $4.31 |
| 2018 | $2.00 | −$0.42 | $0.37 | −$0.44 | — | $3.90 |
| 2019 | $2.01 | −$0.19 | $0.20 | −$0.17 | — | $4.02 |
| 2020 | $2.13 | −$0.14 | $0.56 | −$0.38 | — | $3.92 |
| 2021 | $2.53 | −$0.01 | $0.34 | −$0.22 | — | $4.21 |
| 2022 | $2.40 | −$0.32 | $0.51 | −$0.71 | — | $3.92 |
| 2023 | $2.26 | −$0.75 | $0.24 | −$0.85 | — | $3.22 |
| 2024 | $3.24 | −$0.26 | $0.06 | −$0.01 | — | $3.06 |
| 2025 | $3.06 | −$0.12 | $0.14 | $0.14 | — | $2.99 |